Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018	2017	2016
Net Income	-114.53	-122.18	-93.67	-85.66	-53.85	-28.05	-13.33
Depreciation & Amortization	2.06	2.22	2.03	1.76	1.94	0.83	0.5
Share-Based Compensation	15.16	15.85	8.47	8.17	0	1.54	0.42
Other Operating Activities	-3.93	7.39	10.11	3.75	4.64	2.41	0.1
Operating Cash Flow	-101.24	-96.73	-73.06	-71.98	-47.28	-23.27	-12.31
Capital Expenditures	-0.62	-1.52	-1.32	-3.03	-5.46	-1.74	-1.25
Acquisitions	0	0	0	0	0	0	10.49
Change in Investments	-	-	-	-55	-217.34	-	-
Other Investing Activities	-	0.04	0.01	110	162.67	-	0.03
Investing Cash Flow	-0.62	-1.48	-1.32	51.97	-60.13	-1.74	9.26
Common Stock Issued	84.54	81.75	54.99	0	75.83	0	0
Other Financing Activities	-2.89	15.79	10.47	4.99	86.18	48.97	15.74
Financing Cash Flow	81.66	97.54	65.47	4.99	162.01	48.97	15.74
Net Cash Flow	-20.66	-0.67	-8.91	-15.02	54.61	23.96	12.69
Free Cash Flow	-101.86	-98.24	-74.38	-75.01	-52.74	-25.01	-13.56
Free Cash Flow Per Share	-23.37	-37.14	-37.68	-46.84	-48.23	-133.34	-95.70

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.